Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis.

Yun, Hwi-Yeol; Chang, Vincent; Radtke, Kendra K; Wang, Qianwen; Strydom, Natasha; Chang, Min Jung; Savic, Radojka M

Yun, Hwi-Yeol; Chang, Vincent; Radtke, Kendra K; Wang, Qianwen; Strydom, Natasha; Chang, Min Jung; Savic, Radojka M.

Afiliação

Yun HY; Department of Pharmacy, College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea.
Chang V; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Radtke KK; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Wang Q; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Strydom N; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Chang MJ; Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea.
Savic RM; Department of Pharmaceutical Medicine and Regulatory Science, Yonsei University, Incheon, Republic of Korea.

Open Forum Infect Dis ; 9(3): ofab660, 2022 Mar.

Article em En | MEDLINE | ID: mdl-35146045

Palavras-chave

QT prolongation model; lung lesion distribution model; moxifloxacin; multidrug resistance tuberculosis (MDR-TB); population pharmacokinetics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google